Medpage Today on MSN7mon
Multiple Sclerosis Predicted by Autoantibody Signature
A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS) long before clinical symptoms ...
Labroots13d
New Advances in COVID-19 Diagnostics
The findings were reported in Science Translational Medicine. The researchers wanted to measure autoantibody levels in nasal ...
Labroots24d
Predicting Therapy Outcomes with Autoantibody Biomarkers in Melanoma
Join Dr. Osman in this engaging webinar as she delves into the cutting-edge world of autoantibody profiling to uncover predictive signatures of response and toxicity of immune checkpoint inhibitors ...
Pharmabiz10d
US FDA grants breakthrough therapy designation to Johnson & Johnson’s nipocalimab to treat adults living with moderate-to-severe Sjögren's disease
This milestone underscores our unwavering commitment to develop novel, transformational therapies that may help address significant unmet need for patients living with autoantibody-driven diseases." ...
Lupus Foundation of America2d
First Person Dosed with Investigational Therapy, ADI-001, for Treatment of Lupus Nephritis
Adicet Bio announced the first person with lupus nephritis (LN) has been dosed with ADI-001, an investigational allogeneic gamma delta CAR T cell therapy that targets B cells. The phase 1 study of ADI ...
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...